2012-02-15_15-17-38_225-e1509748037866.jpg

Shoulder Arthroplasty Market – Global Opportunity Analysis and Industry Forecast, 2017-2023

Posted On November 3, 2017 By OrthoSpineNews In Recon /  

LONDON, Nov. 2, 2017 /PRNewswire/ —

Shoulder Arthroplasty Market by Procedure (Partial Shoulder Arthroplasty, Total Shoulder Arthroplasty, and Revision Shoulder Arthroplasty), Device (Shoulder Arthroplasty Resurfacing Implants, Shoulder Arthroplasty Trauma Devices, and Shoulder Arthroplasty Platform Systems), Indication (Arthritis, Fracture/Dislocation, Rotator Cuff Tear Arthropathy, Hill Sachs Defect, and Other), and End User (Hospitals & Clinics, and Outpatient Surgical Centers) – Global Opportunity Analysis and Industry Forecast, 2017-2023

Download the full report: https://www.reportbuyer.com/product/5139386

Shoulder arthroplasty or shoulder replacement is a surgical procedure, which assists in the replacement of damaged ball and socket joint located in the shoulder. This is done using a prosthesis, usually consists of polythene and metal components. Shoulder arthroplasty has become a preferred modality of surgeons for the treatment of osteoarthritis, rheumatoid arthritis, and osteonecrosis, as these procedures have yielded significant and reproducible results. Large-scale adoption of total shoulder arthroplasty procedures for the treatment of people suffering from arthritis has highly contributed to the market growth.

Increase in prevalence of shoulder arthritis and rise in geriatric population worldwide drive the growth of the global shoulder arthroplasty market. In addition, rise in awareness towards shoulder arthroplasties and advancements in the surgical techniques supplement the market growth. However, increase in risk of postoperative complications, such as neurologic injury and hematoma, hampers the market growth. Conversely, rise in investments by the key players to manufacture shoulder arthroplasty devices in the developing economies is expected to offer lucrative opportunities for the market growth. The global shoulder arthroplasty market was valued at $1,080 million in 2016, and is expected to reach $1,814 million by 2023, registering a CAGR of 7.6% from 2017 to 2023.

The shoulder arthroplasty market is segmented based on procedure, device, indication, end user, and region. On the basis of procedure, the market is divided into partial shoulder arthroplasty, total shoulder arthroplasty, and revision shoulder arthroplasty. By device, it is categorized into shoulder arthroplasty resurfacing implants, shoulder arthroplasty trauma devices, and shoulder arthroplasty platform systems. Depending on indication, it is classified into arthritis, fracture/dislocation, rotator cuff tear arthropathy, Hill Sachs defect, and other. As per end user, it is fragmented into hospitals & clinics and outpatient surgical centers. Regionally, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The total shoulder arthroplasty (TSA) segment accounted for the highest share in the global shoulder arthroplasty market in 2016, and is anticipated to register a highest CAGR of 9.2% from 2017 to 2023. This is attributed to increase in adoption of total reverse shoulder arthroplasty.

In addition, shoulder arthroplasties are majorly performed in hospitals and clinics, and thus this segment generated the highest revenue. In the recent years, Asia-Pacific witnessed rapid growth in the shoulder arthroplasties market, owing to steady increase in the population suffering from various forms of arthritis. Moreover, increase in investments by the key players of Japan and India to develop shoulder arthroplasty devices is projected to offer lucrative opportunities for the expansion of the market.

KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the global shoulder arthroplasty market with the current trends and future estimations to elucidate the imminent investment pockets.
Comprehensive analysis of the factors that drive and restrict the market growth is provided.
Comprehensive quantitative analysis of the industry is provided from 2016 to 2023 to assist stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the key segments of the industry helps to understand the trends in shoulder arthroplasty devices and procedures performed globally.
Key players and their strategies are provided to understand the competitive outlook of the industry.

KEY MARKET SEGMENTS

By Procedure
Partial Shoulder Arthroplasty
Partial Resurfacing
Hemi Resurfacing
Partial-mid Head
Stemmed Hemi
Total Shoulder Arthroplasty
Total Resurfacing
Total-mid Head
Total Conventional
Total Reverse
Revision Shoulder Arthroplasty

By Device
Shoulder Arthroplasty Resurfacing Implants
Shoulder Arthroplasty Trauma Devices
Shoulder Arthroplasty Platform Systems

By Indication
Arthritis
Osteoarthritis
Rheumatoid Arthritis
Other Inflammatory Arthritis
Fracture/Dislocation
Rotator Cuff Tear Arthropathy
Hill Sachs Defect
Other

By End User
Hospitals & Clinics
Outpatient Surgical Centers

By Region
North America
U.S.
Canada
Mexico
Europe
UK
France
Germany
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
South Africa
Turkey
Saudi Arabia
Rest of LAMEA

KEY MARKET PLAYERS
Wright Medical Group, Inc. /Tornier Inc.
Integra LifeSciences Corporation
Zimmer Biomet
Johnson & Johnson (DePuy Synthes)
Arthrex, Inc.
Smith and Nephew Plc.
Conmed Corporation
DJO Global
Evolutis
Exactech, Inc.

The other players in the value chain include (profiles not included in the report)
Implantcast GmbH
Lima Corporate
Medacta International
Kinamed Incorporated
Corin
Imascap SAS
Catalyst Orthoscience
Biotechni
Cayenne Medical
BioTek Instruments, Inc.

Download the full report: https://www.reportbuyer.com/product/5139386

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
https://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

SOURCE ReportBuyer

Related Links

http://www.reportbuyer.com

Read More
a_769e29858af7ac20fa6ebc6c418aa602.jpg

Medacta Announces FDA Clearance and First Surgeries Utilizing 3DMetalTM Tibial Cones for Knee Revision

Posted On November 3, 2017 By OrthoSpineNews In Recon, Top Stories /  

November 03, 2017

CASTEL SAN PIETRO, Switzerland–(BUSINESS WIRE)–Family-owned orthopedics leader Medacta International today announced the first surgeries utilizing its recently FDA-cleared 3DMetalTM Tibial Cones for knee revision surgery. The 3DMetal Tibial Cones can be used for structural support in areas of bone deficiencies that may compromise revision implant fixation, and are indicated for use with Medacta’s GMK Revision and GMK Hinge Knee systems, as well as the GMK tibial extension stems and offset. The first surgeries utilizing this technology were performed by Kevin Hardt, M.D., and David Manning, M.D., of the Northwestern University Feinberg School of Medicine in Chicago, Illinois and Dragan Jeremic, M.D., of St. Vincenz Krankenhaus Brakel in Brakel, Germany.

“Medacta’s 3DMetal Tibial Cones recreate a proximal structural foundation for the intended revision implant by achieving proximal fixation and force transmission in the remaining host bone,” said Dr. Manning, a revision knee specialist and designer of the 3DMetal Tibial Cones. Dr. Hardt added: “The instrumentation was straightforward to use and complementary to my typical revision workflow. I was impressed with the surgical press fit of the implant.”

A Medacta innovation, 3DMetal is a three-dimensional advanced biomaterial based on 3D printing technology that enables direct structural and functional connection with the bone through an interconnecting pore structure similar to the cancellous bone structure. With this new solution, the Medacta knee portfolio allows surgeons to address multiple revision scenarios, including even the most challenging of cases.

Dr. Jeremic, also an expert in primary and revision total knee replacement, commented: “I am very satisfied with this new implant and the result. From now on, this will be an excellent option for my patients.”

“It is Medacta’s mission to be a partner for our surgeons, even in the most challenging scenarios,” said Francesco Siccardi, Executive Vice President of Medacta International. “With our innovative 3DMetal technology, we have extended the range of advanced solutions for our surgeons and we will continue to do so in the future.”

Medacta will launch the 3DMetal Tibial Cones for the U.S. market at the American Academy of Orthopaedic Surgeons Annual Meeting, which will be held in New Orleans in March 2018. The Medacta Shoulder System, announced earlier this month, will also be introduced at the meeting. For more information about Medacta, please visit medacta.com or follow @Medacta on Twitter.

About Medacta International

Medacta® International is a world leading manufacturer of orthopedic implants, neurosurgical systems, and instrumentation. Medacta’s revolutionary approach and responsible innovation have resulted in standard of care breakthroughs in hip replacement with the AMIS®system and total knee replacement with MyKnee® patient matched technology. Over the last 10 years, Medacta has grown dramatically by taking a different approach and placing value on all aspects of the care experience from design to training to sustainability. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 30 countries. To learn more about Medacta International, please visit www.medacta.com or follow @Medacta on Twitter.

Contacts

For Medacta International, Inc.
Jill Bongiorni, (516) 729-2250
Jill@torchcomllc.com

Read More
643324649_780x439.jpg

Corin completes Joint Venture Agreement with Ossis to deliver life-changing personalised reconstructive solutions

Posted On November 2, 2017 By OrthoSpineNews In Recon /  

Corin, a global orthopaedic manufacturer and leader in functional implant positioning has announced a joint venture agreement with Ossis, a New Zealand-based implant maker. With more than 15 years clinical history Ossis is one of the leaders in design and manufacturing of personalised solutions for complex revision surgery and tumour resection.

Since 2007 Ossis has used advanced technologies to custom design and manufacture titanium bone and joint implants with over 200 successful implantations to date worldwide. Corin has recently developed an advanced 3D printing technology to manufacture their upcoming revision hip acetabular solution Trinity Plus™. The two companies are now partnering to provide the same cutting-edge technology for customised implants.

“With Corin’s portfolio we are able to provide personalised hip and knee solutions from bone preserving primary implants to revisions. Through this agreement we will extend our ability to support surgeons in the treatment of patients that require massive reconstruction” said Stefano Alfonsi, Chief Executive Officer of Corin. “The objective is to combine the long experience of Ossis in custom-made implants with our connected information infrastructure to improve surgeons’ abilities to perform these life-changing procedures worldwide”.

Ossis Managing Director Paul Morrison said “Communication, lead-time, and accuracy are all considered the enemy of a successful outcome for customised implants. Corin has several technology platforms that will complement and enhance the Ossis Custom Implant Service. We see this as an exceptional opportunity for those surgeons who consider custom implants the best option for their patient’s future quality of life.”

The joint venture with Ossis represents another important milestone for Corin in the creation of an interconnected network of technologies to provide solutions that maximises value for patients, surgeons and healthcare providers.

For more information, visit www.coringroup.com.

About Ossis

Ossis is Australasia’s only ISO 13485 certified medical technology company, dedicated to the design and manufacture of Patient Specific Custom Implants. We offer over 15 years of clinical experience and expertise to our customers, helping them protect, restore or improve their patient’s long-term mobility.

Our team of engineers are recognised, not only for the quality and effectiveness of our products, but also for the high level of support we provide to our customers.  Great results are achieved through a combination of a good anatomical understanding and listening to our surgeons. We aspire to be recognised as a leader in the design and manufacture of custom orthopaedic implants.

Read More
Maxx_web1-1-e1509645121588.jpg

Maxx Orthopedics Announces First International Surgeries of its Freedom® PCK Revision System

Posted On November 2, 2017 By OrthoSpineNews In Recon /  

PLYMOUTH MEETING, PA. (PRWEB) NOVEMBER 01, 2017

Ahead of the AAHKS 2017 Annual Meeting this week in Dallas, TX, Maxx Orthopedics, Inc., today announced that the Freedom® PCK Revision System has now been made available globally, with the first surgeries performed in India and several Gulf countries, including Oman and the United Arab Emirates.

The Freedom PCK Revision System combines the Freedom Stemmed Tibial components with the patent-pending PCK femoral components and constrained liners, to create one of the most bone conserving, versatile revision knee systems available on the market. Designed in collaboration with a global surgeon team, the PCK Revision System has been available for use in the United States since early 2016.

The first case in India was performed by Dr. Hemant Wakankar at Max Elite Hospital in Chandigarh. “The design of the PCK is exceptional and its features are particularly well suited for my patients. I believe they will have better range of motion even after a revision surgery because of this unique progressive constraint system. It gives me the opportunity to provide better results for my patients,” said Dr. Wakankar.

Dr. Carl Becker, a leading surgeon at Penn Medicine’s Lancaster General Hospital in Lancaster, PA, is one of the key design surgeons for the PCK, and has traveled internationally for peer-to-peer discussions on the system.  “I have had the pleasure of working with Maxx’s global team to help design a revision implant which delivers significant benefits for the surgeon and patient. Furthermore, our instruments make the surgery intuitive, and I am excited that this solution is now being offered to my colleagues all over the world.”

“Our team is thrilled by the early clinical success of this system and we are excited to continue our global rollout. The PCK is a revision knee designed with the needs of today’s patients AND today’s economic realities in mind. It’s smart innovation, and this has become a hallmark for our company,” said Ashesh Shah, CEO of Maxx Orthopedics.

For more information please visit http://maxxmed.com.

About Maxx Medical Maxx Medical Pvt. Ltd. (“Maxx Medical”) develops and markets innovative orthopedic medical devices on an international scale. The company is focused on providing state-of-the-art implants and related solutions that best restore patient mobility while accommodating lifestyle, anatomical and economic needs. Maxx Medical is the parent company of Maxx Orthopedics, Inc., the manufacturer of the Freedom Knee® System.

Read More
HRS-Control-iGad-pr.jpg

Exactech Announces Successful First Revision Knee Replacement Surgery with Truliant® Instrumentation

Posted On November 2, 2017 By OrthoSpineNews In Recon /  

November 01, 2017

GAINESVILLE, Fla.–(BUSINESS WIRE)–Exactech (Nasdaq: EXAC), a developer and producer of bone and joint restoration products and biologic solutions for extremities, knee and hip, is pleased to announce that the first revision knee surgery was performed using the company’s award-winning Truliant® instrumentation. Orthopaedic surgeons will have a chance to experience the Truliant primary and revision systems through live mechanical demonstrations Nov. 2-5 at the American Association of Hip and Knee Surgeons (AAHKS) Annual Meeting, Booth #908 in Dallas, Texas.

The first surgery was performed by revision knee replacement specialist Ronald Hillock, MD, at the Nevada Orthopedic and Spine Center in Las Vegas. According to Dr. Hillock, “The case ran smoothly, and I was able to re-establish the patient’s joint line in just over an hour. Truliant is a well-thought-out, comprehensive system that allowed me to easily position the implant in the optimal position for the patient. The new offset couplers and metaphyseal cones allows for managing the complexities of implant fixation and bone loss.”

Developed through close collaboration with a team of design surgeons and Exactech engineers, Truliant supports both mechanical and computer-assisted surgical approaches and now addresses the continuum of total knee arthroplasty – from primary to revision.

“In designing Truliant, we were met with the paradox of trying to be simple and easy to understand, while still providing the surgeon and patient with all the options they need,” said Daniel C. Allison, MD, oncologic orthopaedic surgeon and Truliant design team member. “I think Exactech did a great job of bringing those things together and threading that needle, so that everything is intuitive without being overly complex. Combining that simplicity, while maintaining a wide variety of options was a hard challenge, but Exactech mastered it beautifully.”

The Truliant primary knee system made its clinical debut in May and has been used in more than 600 surgeries during the pilot launch. Both the primary and revision systems are expected to have full U.S. market availability in 2018. For more information, visit www.TruliantKnee.com.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at http://www.exac.com.

Contacts

Exactech
Jody Phillips, 352-377-1140
Executive Vice President of Finance & Chief Financial Officer
or
Exactech
Priscilla Bennett, 352-377-1140
Priscilla@exac.com

Read More
Claris-Reflex-Senior-Home-org-1-e1509573988893.png

Claris Reflex Launches to Provide 24/7 Coaching and Monitoring of TKR Patients at Home

Posted On November 1, 2017 By OrthoSpineNews In Recon /  

Washington, United States, (November 1st, 2017) – Today Claris Healthcare is launching Claris Reflex, a new medical device and patient monitoring system to help orthopedic practices across North America monitor the recovery of Total Knee Replacement (TKR) patients. Claris Reflex is the only system to offer continuous coaching at home, from surgical preparation to postoperative care.

Designed specifically for patients aged 65+, Claris Reflex is a coaching system, which allows providers to better manage patients under the new bundled payment for total knee replacement programs including BPCI, CJR and private insurance. Patients are given a wearable sensor and an easy to use tablet; caregivers are provided access to an online dashboard that allows them to monitor patients remotely 24/7.

 

Geof Auchinleck, CEO, Claris Healthcare, said: “The thought of total knee replacement surgery can be a source of anxiety for a lot of patients, especially those over the age of 65. Claris Reflex removes this fear and allows patients to confidently and independently manage their pre and post-surgical recovery in their own home. Claris Reflex benefits everyone – first and foremost the patients, but also the clinicians, hospitals, and care providers.”

For clinics, better patient compliance saves time and money by reducing the number of patient days in hospital and skilled nursing facilities (SNF), as well as, reducing the number of physical therapy, home care and emergency room visits.

Dr. Dimmig, of EmergeOrtho, Durham, NC, one of the first orthopedic clinics to use Claris Reflex, said, “Claris Reflex is a significant innovation that has allowed us to streamline care for our knee replacement patients.  It’s unlike any patient management solution we’ve used before: for our older patients, the product is intuitive and simple to use; and for our staff, it’s enabling us to provide the best care possible while reducing our overall costs.”

Some key features of Claris Reflex include:

  • Activity tracking sensor: monitors each flexion and extension of the patient’s knee, as well as, body position (walking, standing, lying and sitting), icing temperature and compliance with exercises
  • Wireless patient connectivity: patients wear the sensor anywhere, 24/7 for their 8 week recovery: they are not restricted by a tethered system and the data uploads automatically when in range of the tablet
  • Simple patient dashboard: providers can quickly see in real time how patients are progressing with their rehabilitation and be alerted to any issues with their recovery
  • Objective data reporting: enables providers to manage care costs and monitor post-acute outcomes
  • Secure communication: patients and providers can send text messages, videos or photos; request a call and/or an appointment with a provider; and make video calls (if enabled)

For more information, please visit www.clarisreflex.com

 

About Claris Healthcare

Claris Healthcare uses technology to provide an interactive healthcare approach focused on overall patient wellbeing. Unlike other patient facing software applications, Claris Healthcare is focused on developing intuitive solutions specifically designed for the increasing number of older patients. Claris Healthcare began by providing Claris Companion, an intuitive tablet for seniors that could be remotely managed by family members. Since then, it has expanded the platform into remote patient monitoring by helping home care operators care for their Chronic Care clients. Claris Healthcare has already developed platforms for social and chronic care, and brings this experience to Claris Reflex as its first move into the acute care space.

 

Media Contact
Yulu Public Relations
Nora Eastwood
nora@yulupr.com
(+1) 604-558-1656

—

Read More
Surgery-Render.png

Intellijoint Surgical Inc. Receives FDA Clearance for Revision THA with intellijoint HIP®

Posted On November 1, 2017 By OrthoSpineNews In Recon, Regulatory, Top Stories /  

WATERLOO, ON, Nov. 1, 2017 /PRNewswire/ – Intellijoint Surgical®, a medical technology company, is pleased to announce that it has received FDA Clearance for revision Total Hip Arthroplasty (THA) with its intellijoint HIP® System. A 3D Mini-Optical Navigation System, intellijoint HIP® provides surgeons with precise measurements for cup position, leg length and offset for THA. Requiring no pre-operative or intra-operative imaging, intellijoint HIP can be used with any implant manufacturer, and for any primary or revision THA.

The revision indication provides surgeons with the ability to evaluate existing THA components to inform intra-operative decision making. The possibility to leave existing components in place can greatly reduce risk to the patient and can contain cost for the hospital.  Other image based technologies are not suitable for revision THA as existing components create distortion to pre-operative images, making them unusable for critical patient registration.

“intellijoint HIP for revision gives me accurate positioning information about the existing cup. I can then determine which acetabular components need to be removed due to the component being malpositioned,” explained said Dr. Wayne Paprosky, Midwest Orthopaedics at Rush and a member of Intellijoint’s scientific medical advisory board.  “I can document the position to defend why I removed or retained the component. When I am able to leave the cup in place, particularly in high risk patients, the risk of complication is greatly reduced and the procedure is significantly shortened.”

intellijoint HIP is available for Anterior, Posterior and Lateral approaches and can be used on primary and now revision THA. This milestone supports Intellijoint Surgical’s mission of making intellijoint HIP accessible to every surgeon and every patient.

“Our core technology is well suited for revision surgery as it provides accurate intra-operative information without relying on pre-operative x-rays or imaging of any kind,” added Intellijoint Surgical CEO Armen Bakirtzian. “Image-based robotics and navigation systems rely heavily on pre-operative imaging, which could result in significant inaccuracies due to image distortion by metal from the existing components”.

Visit Intellijoint Surgical at the upcoming American Association of Hip and Knee Surgeons (AAHKS) annual meeting (booth 100) in Dallas, Texas from November 3rd to 4th to learn about the cutting-edge technology behind intellijoint HIP.

About Intellijoint Surgical:

Intellijoint Surgical® develops and commercializes surgical navigation solutions. Intellijoint’s flagship product, intellijoint HIP® provides surgeons with real-time, intraoperative measurements to ensure proper positioning of orthopaedic implants during Total Hip Arthroplasty. Intellijoint is committed to driving clinical results through the development of solutions that are accessible, fast, and easy-to-use. Intellijoint is setting the new standard in miniature 3D surgical navigation.

Intellijoint Surgical is the recipient of the 2015 North American Frost & Sullivan Enabling Technology Leadership Award and the Futurpreneur Shopify True Grit Award 2016.

SOURCE Intellijoint Surgical Inc.

Related Links

https://www.intellijointsurgical.com/

Read More
OMNI_paramount_450-1.jpg

OMNIlife science™, Inc. Announces First Clinical Evaluations of Revolutionary OMNIBotics® Active Spacer Robotic Tissue Balancing Device

Posted On October 31, 2017 By OrthoSpineNews In Recon, Robotics, Top Stories /  

RAYNHAM, Mass., Oct. 31, 2017 /PRNewswire/ — OMNIlife science, Inc. (“OMNI™”), a privately-held, established medical technology company targeting the $15 billion global hip and knee replacement device market, announced today that they have begun clinical evaluations of their exclusive OMNIBotics Active Spacer robotic tissue balancing device at three U.S. sites. This technology received 510(k) clearance from the FDA on September 1, 2017.

The OMNIBotics Active Spacer, in clinical use since March in Australia, provides the surgeon with a quantitative tool to actively manage the soft tissue envelope with dynamic real-time feedback. When combined with the accuracy of alignment and bone cuts provided by the OMNIBotics system, the result is a completely customized procedure from both a skeletal and a soft tissue perspective.

“I believe that the active spacer technology is the tool we have been looking for to create even better predictability and reproducibility for knee replacement surgery,“ said Jeffrey M. Lawrence, M.D. Viroqua, WI. “I’m very excited to offer this system to my patients.”

Of his early experience, John M. Keggi, MD, Middlebury, CT said, “The active spacer technology is a great step forward that brings the most advanced measurement and analysis tools directly to each patient and surgeon right in the operating room. It’s an unprecedented, real-time evaluation of the knee that optimizes each step of the procedure.”

Studies indicate that a significant percentage of knee replacement patients do not achieve full satisfaction even with well-placed implants. One potential contributing factor is sub-optimal soft tissue balancing.

“The active spacer is an amazing new technology for knee replacement. It actually shows your surgeon, in real time, how tight or loose your knee is on each side as it bends. This information is then fed into a robot, which plans how your knee is replaced on an individual basis for optimum results,” said Amber Randall, MD an orthopedic surgeon in Arizona.

OMNI, a pioneer in robotic-assisted total knee replacement, now offers the only robotic technology that quantitatively drives the total knee replacement surgical procedure with both alignment and ligament balancing. Dr. Randall continues, “I believe that this revolutionary, never before seen technology will get us not one–but several–steps closer to the Holy Grail of knee replacement: the freely moving, perfectly stable and pain free knee.”

ABOUT OMNI

OMNI is a privately held company with a proprietary robotic platform, OMNIBotics®, which allows surgeons to conduct patient-specific total knee surgery designed to enhance patient satisfaction and reduce hospital costs. In addition, OMNI designs, engineers, manufactures and distributes a wide range of proprietary hip and knee implants and is focused on providing cutting edge technologies to transform outcomes in joint replacement surgery and enhance a surgeon’s ability to help patients live active and pain-free lives. For more information about OMNI, please visit www.omnils.com.

FORWARD LOOKING STATEMENTS

Statements in this press release concerning the future business, operations and prospects of OMNIlife science, Inc., including its plans specific to OMNIBotics systems, as well as statements using the terms “plans,” “believes” or similar expressions are “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon management’s current expectations and are subject to a number of factors and uncertainties. Information contained in these forward-looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors include, among others, changes in competitive conditions and pricing in OMNI’s markets, decrease in the demand for OMNI’s products, delays in OMNI’s product research and development cycles, decreases in the use of OMNI’s principal product lines or in procedure volume, unanticipated issues in complying with domestic or foreign regulatory requirements related to OMNI’s current products or securing regulatory clearance or approvals for new products or upgrades or changes to OMNI’s current products, the impact of the United States healthcare reform legislation on hospital spending and reimbursement, any unanticipated impact arising out of the securities class action or any other litigation, inquiry, or investigation brought against OMNI, increases in costs of OMNI’s sales force and distributors, and unanticipated intellectual property expenditures required to develop, market, and defend OMNI’s products. OMNI cannot guarantee any future results, levels of activity, performance or achievement. OMNI undertakes no obligation to update any of its forward-looking statements after the date of this press release.

CONTACT

Cindy Holloway, Director of Marketing Communications Phone: (508) 824-2444
cholloway@omnils.com

 

SOURCE OMNIlife science, Inc.

Read More
643324649_780x439.jpg

Corin Group acquire Belgium & Luxemburg large joint business unit of MBA NV

Posted On October 19, 2017 By OrthoSpineNews In Extremities, Recon, Spine, Top Stories /  

18 October 2017

Corin Group, after the successful acquisition of the Tornier Hip and Knee business is announcing a further European expansion by acquiring the large joint business unit of MBA Belgium & Luxemburg NV.

Over the last 7 years MBA has successfully distributed the Corin portfolio. The team have gone from strength to strength, expanding and developing solid collaborative relationships with key surgeons throughout the countries. The combination of Corin technologies and the MBA team’s passion for orthopaedics will deliver greater value to the Belgium and Luxemburg Orthopaedic community.

Stefano Alfonsi, Chief Executive Officer of Corin commented “With MBA’s, responsive service and solid working relationships they are well placed to engage their attentive audience with Corin’s world leading innovative technologies. We are delighted to welcome the team who are transitioning to Corin from MBA and look forward to building an even stronger surgeon focused organisation.”

Paul Griffin, International Business Director, MBA, commented, “Building on MBA’s success in Belgium & Luxemburg in the recent past,  Corin’s involvement will streamline the representation from MBA and Tornier to a single Corin entity, simplifying the customer experience, and enabling more surgeons to engage with Corin’s Ecosystem of  ground breaking technologies’.”    

About Corin

Since its inception, Corin has led the way in orthopaedic innovation — providing a faster, positive and more assured return to quality of life for people all over the world. Today, as a dynamic, growing, global business, Corin’s approach is revolutionising orthopaedics.

We offer a unique combination of clinically-proven hip, knee, ankle and shoulder solutions and world-leading technologies that enable patients, surgeons and healthcare providers to connect more closely than ever.

The deep insight we gain, understand and share at every stage of the connected orthopaedic experience leads to advanced, patient-specific solutions that exceed expectations, maximise value in healthcare and positively impact lives.

About MBA

MBA is a leading company in the European medical and surgical technology field. Our objective is to create value for the specialist through technology, service and sharing knowledge.

MBA currently has two divisions:

MBA

The Company began by specialising in providing complete solutions for Orthopaedic and Neurosurgeons via a full range of product lines for the following specialities:

  • Knee
  • Hip
  • Shoulder
  • Other joints: Elbow, Hand, Wrist, Foot and Ankle.
  • Tumour and Extremity Reconstruction
  • Biomaterials
  • Spine
  • Trauma

BIOSER

This Division provides solutions for nine surgical specialties: Anaesthesiology, General Surgery, Cardiovascular Surgery, Thoracic surgery, Urology, Gynaecology, Obstetrics, ENT, Plastic Surgery and Emergency Medicine.

Read More
microportorthopedicsbuilding-500.jpg

MicroPort Orthopedics Announces Industry Symposium at American Association of Hip and Knee Surgeons

Posted On October 19, 2017 By OrthoSpineNews In Recon /  

ARLINGTON, TENNESSEE, October 17, 2017 – MicroPort Orthopedics, a medical device company that develops and manufactures cutting-edge joint replacement implants and approaches, will host an industry symposium at the annual American Association of Hip and Knee Surgeons (AAHKS) meeting titled, “Tackling Your Toughest Cases in the Changing Healthcare Landscape” on Friday, November 3, 2017.

The symposium will feature four surgeon panelists, invited by MicroPort Orthopedics, who will discuss management of the toughest hip and knee replacement cases in an orthopedic landscape that faces evolving healthcare trends including new orthopedic technology and innovation, changing regulations and payment models, and the shift to outpatient care.

“Everyone in the medical device industry recognizes that the healthcare marketplace is evolving at breakneck speed, and we are constantly in pursuit of better and more efficient ways to adapt to these changes,” said Aurelio Sahagun, President, MicroPort Orthopedics. “We’re grateful to have not only a platform at AAHKS to discuss these innovations but also four renowned orthopedic surgeons who can speak to industry trends, best practices, and new approaches to their work.”

The symposium will be moderated by Stephen Murphy, MD, an orthopedic surgeon at New England Baptist Hospital, who will also be speaking about his experience in the Bundled Payments for Care Improvement (BPCI) Initiative. Joining Dr. Murphy will be, Judd Cummings, MD, Jimmy Chow, MD and Nicolas Noiseux, MD, MS, FRCSC. Dr. Cummings, an orthopedic surgeon at Specialty Orthopedic Surgery, will examine key considerations when taking on tough cases. Dr. Chow, a hip & knee specialist at Chow Hip and Knee, will discuss the importance of powerful surgical philosophy for Total Hip Arthroplasty. Dr. Noiseux, an associate professor in the department of Orthopedics and Rehabilitation at the University of Iowa Hospitals and Clinics, will be talking about anterior-posterior stability in complex primary cases. Following the discussion, the surgeons will answer questions asked by the audience.

About MicroPort Orthopedics

Established in January 2014, MicroPort Orthopedics Inc. is the fifth largest multinational producer of hip and knee implants and a proud member of the MicroPort Scientific Corporation family of companies. From its headquarters in Arlington, Tennessee, MicroPort Orthopedics develops, produces, and distributes innovative OrthoRecon products. The company’s U.S.-based manufacturing and logistics capabilities deliver high quality hip and knee products to patients and their doctors in over 60 countries, including the U.S., EMEA, Japanese, Latin American and China markets. For more information about MicroPort Orthopedics, visit http://www.ortho.microport.com/ or follow the company on Twitter at @MicroPortOrtho.

About MicroPort Scientific

MicroPort Scientific Corporation is a leading medical device company focused on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, MicroPort maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a patient-oriented global enterprise that improves and reshapes patient lives through application of innovative science and technology. For more information, please refer to: http://www.microport.com.

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words “believe,” “intend,” “expect,” “anticipate,” “project,” “estimate,” “predict,” “is confident,” “has confidence” and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort’s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.

Copyright © 2017 MicroPort Scientific Corporation

 

Ryan Donovan | Assistant Account Executive

O: 617-374-8800 x102

M: 857-294-2561

Email:  rdonovan@lavoiehealthscience.com | Twitter: @lavoiegroup
LinkedIn: https://www.linkedin.com/company/lavoie-group

Website: http://www.lavoiehealthscience.com

Read More